Influence
July 14, 2025

Risk for metachronous advanced neoplasia in patients with a modified definition of advanced adenoma: data from the New Hampshire colonoscopy registry

Thomas Imperiale

Published in the Clinical Gastroenterology and Hepatology. Here is a link to the article.

Regenstrief Institute authors: Thomas Imperiale,

A new analysis using data from the New Hampshire Colonoscopy Registry examined the risk of metachronous advanced neoplasia (AN) and colorectal cancer (CRC) in individuals with different subtypes of advanced adenomas (AA). The study focused on comparing patients with 10–19 mm tubular adenomas (TA) to those with modified AA characteristics—high-grade dysplasia (HGD), villous histology, or TA >20 mm.

Among 35,941 adults who underwent follow-up colonoscopy ≥12 months after index screening, five groups were analyzed. Groups 4 (TAs 10–19 mm) and 5 (modified AA) demonstrated higher adjusted risk for metachronous AN compared to low-risk Groups 1–3 (Rate Ratios: 3.67 and 4.69, respectively), with overlapping confidence intervals.

However, when the outcome was restricted to modified AA, Group 5 had a significantly higher risk than Group 4 (RR=1.52; 95% CI, 1.04–2.22). Hazard ratios for CRC were also higher in Groups 4 and 5 (HR=2.44 and 3.52, respectively) compared to the low-risk reference groups, though their confidence intervals overlapped.

These findings indicate that while both larger TAs and modified AA subtypes are associated with increased AN and CRC risk, individuals with HGD, villous features, or larger adenomas may warrant particular attention. The results suggest a need for more precise risk stratification in surveillance guidelines. Further studies are recommended to refine subgroup risks within the 10–19 mm TA population.

Authors: 

Joseph C Anderson1, Todd A Mackenzie2, Lynn F Butterly3, Thomas F Imperiale4

Affiliations: 

1Geisel School of Medicine at Dartmouth, Hanover, NH; White River Junction VAMC, White River Junction VT; NH Colonoscopy Registry, Lebanon, NH. Electronic address: Joseph.Anderson@Dartmouth.edu.

2Geisel School of Medicine at Dartmouth, Hanover, NH.

3Geisel School of Medicine at Dartmouth, Hanover, NH; Department of Gastroenterology and Hepatology, DHMC, Lebanon, NH; NH Colonoscopy Registry, Lebanon, NH.

4Indiana University School of Medicine, Dept of Med., Div. of Gastro/Hep, Indianapolis, IN; Richard L. Roudebush VA Medical Center; Regenstrief Institute, Inc.

Partners

Related News

image of elderly woman discussing pill bottle with her doctor

American Geriatrics Society unveils updated alternatives to potentially harmful medications for older adults

Regenstrief researcher serves on expert panel providing clinicians, patients and families with credible, actionable alternatives The American Geriatrics Society

LOINC version 2.81 release

Arabic and Czech translations, more than 4,000 new concepts boost global interoperability in latest LOINC® release

Regenstrief Institute’s latest LOINC® content update on August 12, introduces two new linguistic variants: Arabic, for users in Jordan,

Regenstrief President and CEO Rachel Patzer, PhD, MPH.

Regenstrief CEO among national honorees for ground-breaking achievements in transplantation

SAN FRANCISCO – Regenstrief Institute President and Chief Executive Officer Rachel Patzer, PhD, MPH, is among a select group

LOINC 2025 Conference - Montreal, Canada

Regenstrief to host 2025 LOINC® conference in Montréal, Canada, Oct. 7-10

First LOINC conference in Canada — home to one of LOINC’s largest user bases  Regenstrief Institute Health Data Standards